Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gislason, T
Right arrow Articles by Terenius, L
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gislason, T
Right arrow Articles by Terenius, L

Chest, Vol 96, 250-254, Copyright © 1989 by American College of Chest Physicians

ARTICLES

Increased CSF opioid activity in sleep apnea syndrome. Regression after successful treatment

T Gislason, M Almqvist, G Boman, CE Lindholm and L Terenius
Department of Pulmonary Medicine, Uppsala University, Sweden.

The etiology of the SAS is unknown. To test whether endogenous opioids could be pathologically active in SAS, markers of opioid systems were measured in the CSF of 15 patients with SAS and in control subjects. Measured by receptor assay, the concentration of so-called fraction 1 opioid was higher in patients with SAS (3.0 +/- 1.5 pmol/ml; mean +/- SD) than in control subjects (1.1 +/- 0.5 pmol/ml) (p less than 0.01), whereas that of fraction 2 opioid was similar in the two groups. Beta- endorphin-like activity, measured by radioimmunoassay, was somewhat lower in patients with SAS (14.0 +/- 2.8 pmol/ml) than in control subjects (21.8 +/- 7.6 pmol/ml) (p less than 0.05). Six months after surgical treatment of the soft palate, new measurements were made in eight patients. Fraction 2 endorphin and beta-endorphin showed no consistent changes. A decrease in the level of fraction 1 from 4.1 +/- 1.5 pmol/ml to 2.3 +/- 1.0 pmol/ml (p less than 0.02) was noted in those six patients showing a successful clinical course. The data support the hypothesis that in SAS the opioid activity is increased.


This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
I. Ayappa, K. I. Berger, R. G. Norman, B. W. Oppenheimer, D. M. Rapoport, and R. M. Goldring
Hypercapnia and Ventilatory Periodicity in Obstructive Sleep Apnea Syndrome
Am. J. Respir. Crit. Care Med., October 15, 2002; 166(8): 1112 - 1115.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
Y. Tun, W. Hida, S. Okabe, Y. Kikuchi, H. Kurosawa, M. Tabata, and K. Shirato
Inspiratory Effort Sensation to Added Resistive Loading in Patients With Obstructive Sleep Apnea
Chest, November 1, 2000; 118(5): 1332 - 1338.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. W. HUDGEL and S. THANAKITCHARU
Pharmacologic Treatment of Sleep-disordered Breathing
Am. J. Respir. Crit. Care Med., September 1, 1998; 158(3): 691 - 699.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the American College of Chest Physicians.